MediWound (NASDAQ:MDWD) Posts Earnings Results, Beats Estimates By $0.06 EPS

MediWound (NASDAQ:MDWD) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06, FiscalAI reports. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. The firm had revenue of $3.57 million for the quarter, compared to analyst estimates of $6.73 million.

Here are the key takeaways from MediWound’s conference call:

• EscharEx’s VALUE trial remains on track to complete enrollment by the end of Q1 2027, with the interim sample-size reassessment planned for that period; management expects top-line results around mid-2027 if the current study design is unchanged. The latest safety review found no concerns or need for modifications.
• NexoBrid demand and U.S. commercial activity strengthened: Vericel reported its highest quarterly revenue since launch, more than 80 centers have ordered and about 70 have reordered, and BARDA procurement began in Q3. Management said supply constraints, rather than demand, are limiting product sales.
• Global NexoBrid demand currently exceeds manufacturing capacity, and the expanded facility’s commercial supply remains subject to regulatory approval, with a target of the second half of 2027. The company is prioritizing U.S. commercial and government orders while supply remains constrained.
• Q3 revenue fell to $3.6 million from $5.4 million a year earlier, while operating loss widened to $8.5 million from $6.5 million, partly as R&D spending rose to support the VALUE trial. MediWound reported $28.4 million in cash, equivalents and deposits at quarter-end and subsequently raised $17.25 million in a public offering.
• MediWound said a substantial portion of anticipated 2026 revenue depends on funding for a planned U.S.-based manufacturing facility, but it does not know when or whether that funding will be secured. The company said this uncertainty affects its revenue outlook.

MediWound Stock Performance

Shares of NASDAQ:MDWD traded down $0.85 during midday trading on Thursday, hitting $12.97. The company’s stock had a trading volume of 354,543 shares, compared to its average volume of 148,347. The company has a market cap of $168.74 million, a P/E ratio of -7.21 and a beta of 0.07. MediWound has a 12-month low of $11.80 and a 12-month high of $19.70. The business’s 50 day simple moving average is $13.21 and its 200 day simple moving average is $15.08.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on MDWD. TD Cowen restated a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Alliance Global Partners reaffirmed a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Weiss Ratings cut MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Finally, Wall Street Zen raised MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, September 26th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, MediWound currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Insider Transactions at MediWound

In other MediWound news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 9.20% of the company’s stock.

Top MediWound Stories

Investors following MDWD have been watching these stories:

• Positive Sentiment: MediWound said its Phase III VALUE trial of EscharEx® is advancing, with an interim assessment and enrollment completion expected by the end of Q1 2027. Company results and update
• Neutral Sentiment: The company reported a loss of $0.65 per share, narrower than the $0.71 loss analysts expected, but wider than its $0.24 loss a year earlier. The earnings beat offers some support, though the year-over-year deterioration tempers it. Zacks Q3 results
• Negative Sentiment: MediWound reportedly dropped its full-year guidance following the revenue decline, adding uncertainty about near-term performance and likely weighing on investor sentiment. Guidance update

About MediWound

MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.